RT Book, Section A1 Clark, Jeffrey W. A2 Chabner, Bruce A. A2 Longo, Dan L. SR Print(0) ID 1127648839 T1 Pancreatic Cancer T2 Harrison's Manual of Oncology, 2e YR 2016 FD 2016 PB McGraw-Hill Education PP New York, NY SN 9780071793254 LK hemonc.mhmedical.com/content.aspx?aid=1127648839 RD 2024/10/07 AB For most patients, pancreatic adenocarcinoma remains highly lethal and is the fourth leading cause of deaths from cancer in the USA. Less than 5% survive 5 years after diagnosis. Surgical resection is the only curative treatment. However, the cure rate with surgery is only 18%–25% and most patients are not surgical candidates. Patients with unresectable disease can have symptoms palliated by chemotherapy and/or radiation therapy. However, these have not significantly impacted 5-year survival. Improved understanding of pancreatic cancer biology continues to provide new therapeutic ideas. Trials are evaluating whether new approaches to earlier diagnosis or improvements in radiation therapy, chemotherapy (including targeted therapy), and/or immunotherapy (e.g., vaccines, therapy aimed at inhibiting negative immunoregulatory proteins) can impact survival.